The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Emerging immunotherapeutic strategies for multiple myeloma in the frontline and R/R settings
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, gives an overview of the topics discussed at a satellite symposium on emerging treatment strategies in multiple myeloma. Experts spoke on the addition of anti-CD38 monoclonal antibodies to frontline therapy, as well as on the latest updates in BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates and bispecific antibodies in later lines of treatment. There is currently a lot of interest in investigating the efficacy of these immunotherapies in earlier lines of treatment. Data on venetoclax-based combinations for patients with t(11;14) translocation was also shared. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Janssen: Other: Advisory Board; Novartis: Consultancy; Oncopeptides: Consultancy, Honoraria; TeneoBio: Other: Advisory Board; Adaptive Biotechnologies: Other: Advisory Board; BMS: Other: Advisory Board; GSK: Honoraria.
